about
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domainParallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.Pancreatic cancer: epidemiology, genetics, and approaches to screening.Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Consolidation strategies in ovarian cancer: observations for future clinical trials.Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.New drugs for ovarian cancer.Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.Breaking down the evidence for bevacizumab in ovarian cancer.Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy.Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumorsPhase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer PatientsProgression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancerAuthors' reply to Drs. Khattak and MartinIntraperitoneal chemotherapy in older women with epithelial ovarian cancerIncidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinomaA phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerEarly CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapyPreoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancerAlternative Careers for PhysiciansCharacteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
P50
Q24336240-F086317E-6E6E-4A10-AAFD-72CB1E510A78Q27853128-A3CC8A2A-A194-48FF-AAB6-FECCDCB0D811Q33160644-173A54EA-C319-493C-9156-5D1FF681570BQ33381380-757528CE-C27E-47D0-BD03-35BBBDD4E729Q33401443-5C031878-BECE-4031-BF3B-4C31CB3178E5Q34698933-DB5AF092-81B6-4534-ACED-C820DA9E1BAFQ35042301-047D56A4-73C3-4F4A-AC33-4C226B4D1DCCQ36246203-473E7687-EC40-44BB-A526-763C7E051C25Q37178234-5589255B-ABC8-47B4-9440-EA5D5A47DBCAQ37228176-0B58AB8F-E06D-45F0-9F11-0E400F9EE14FQ37408652-0B4D5F3F-013C-4A67-A407-D73883013378Q37730282-39A0D883-CD08-4FAD-9AE7-506E7F14F951Q37969717-72A7BA76-087B-4EE0-83F6-2DE6828B920DQ38108715-DEFA84C9-35DE-495B-BFEE-5137E9523D22Q39299800-52984D3A-5ADA-41EC-B25F-9A38D41DD921Q39816174-191A9338-2C81-493D-A65D-95532CB56A6BQ40100306-1FFB5359-69A0-47D1-9356-F99A14C7AAE1Q40444431-AABDA064-408F-44C2-A55F-D83D86770193Q42882546-B6AA313B-7110-48B6-872A-6D77B59BFD93Q43135873-9279A922-955D-4149-83A5-5B46C1A9DEA5Q45367726-5CA21BA7-29DA-494F-B43D-A30B264E08A9Q46168302-9B6F33EB-AD3C-4DB3-B245-08C8075759F0Q46182385-CF865FD2-C332-4C35-A1A8-4883F7EB2201Q54522094-54E8B0AD-B96C-4657-A0D8-659D38774AD8Q57975528-4EE96A7A-C276-4054-995D-AC7CD9923BBBQ57975533-2DDDEC98-22CF-4456-9566-271EC9800378Q57975538-AE7CCEF6-8266-4B27-8AB2-F20609C50222Q57975542-4C613834-F993-4800-A8D8-681052B00558Q57975544-BD2C2685-063E-4962-B47B-13C9DBEE4662Q57975553-5B88E67D-8DF4-469F-84D7-C3826F83A07CQ57975564-188AA096-6172-4343-9963-642E412D6917Q57975574-DBA993C0-93C5-472A-9C38-AE4E981633E9Q57975577-E2567684-0148-433A-941A-ED0A536B2682Q57975580-B186937C-3EF6-4FC1-8DD2-98AF2F7388FDQ91946612-667940EF-EA25-48DE-8597-A6C0C68D66DE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jason Konner
@ast
Jason Konner
@en
Jason Konner
@es
Jason Konner
@nl
Jason Konner
@sl
type
label
Jason Konner
@ast
Jason Konner
@en
Jason Konner
@es
Jason Konner
@nl
Jason Konner
@sl
prefLabel
Jason Konner
@ast
Jason Konner
@en
Jason Konner
@es
Jason Konner
@nl
Jason Konner
@sl
P106
P1153
6602223733
P21
P31
P496
0000-0002-0720-2719